Polfa Tarchomin predicts next years profits to soar to zł 400 million

After the first six months, they amounted to zł. 161.6 million, which indicates the company has met its financial plan. Comparing, that gross profit equalled zł. 523.000, and considering that the profitability of drug producers reaches 40-50%, Polfa's performance may be deemed very poor. According to the firm's president Andrzej Kleszczewski, it is the result of Polfa's specificity since it manufactures ready products as well as substances for their production. Profits generated from drug production do not divert much from the average in the pharmaceutical sector. In the case of substances profitability is lower but remaining at a decent level. "The two results affect each other, therefore the final performance is low," explained Kleszczewski. (Rzeczpospolita, p. B5) A.Z